Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis . The drug made it to phase III trials...
- Mechanism
- Curator reviewed · 2 references
Odanacatib inhibits cathepsin K, likely by binding to its active site. Cathepsin K is a cysteine protease enzyme which is secreted by osteoclasts. Cathepsin K is responsible for the breakdown of collagen in the bone matrix as part of bone resorption. The inhibition of this enzyme results in decreased bone resorption without affecting bone deposition resulting in increased bone mineral density. This increased bone mineral density strengthens the bone which leads to fewer fractures in osteoporosis.
- Primary indication
- Investigated for use/treatment in osteoporosis.Curator reviewed
- Formula / weight
- C25H27F4N3O3S · 525.56 g/mol (avg)
- Code names
- MK-0822
Resolves to
FWIVDMJALNEADT-SFTDATJTSA-NSMILESCC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#NWhat you can answer from here — as of August 26, 2024
Which drugs share a target with Odanacatib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account